Vincerx Pharma, Inc. Common Stock
VINC
VINC was delisted on the 22nd of April, 2025.
1 hedge funds and large institutions have $2 invested in Vincerx Pharma, Inc. Common Stock in 2025 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 14 closing their positions.
93% less funds holding
Funds holding: 14 → 1 (-13)
93% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 14
100% less capital invested
Capital invested by funds: $117K → $2 (-$117K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BTC
Bank & Trust Company
Litchfield,
Illinois
|
+$20 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SRC
Sage Rhino Capital
Menlo Park,
California
|
-$45.1K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$22.6K |
| 3 |
Goldman Sachs
New York
|
-$16.7K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$10.2K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$7.57K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BTC
1
Bank & Trust Company
Litchfield,
Illinois
| $2 | +$20 | +50 | New |
|
|
SRC
2
Sage Rhino Capital
Menlo Park,
California
| – | -$45.1K | -85,170 | Closed |
|
|
3
Citadel Advisors
Miami,
Florida
| – | -$22.6K | -42,777 | Closed |
|
|
4
Goldman Sachs
New York
| – | -$16.7K | -31,567 | Closed |
|
|
5
Geode Capital Management
Boston,
Massachusetts
| – | -$10.2K | -19,285 | Closed |
|
|
6
Vanguard Group
Malvern,
Pennsylvania
| – | -$7.57K | -14,317 | Closed |
|
|
TSS
7
Two Sigma Securities
New York
| – | -$5.85K | -11,053 | Closed |
|
8
Millennium Management
New York
| – | -$5.72K | -10,798 | Closed |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| – | -$1.59K | -2,997 | Closed |
|
10
BlackRock
New York
| – | -$1.25K | -2,352 | Closed |
|
11
UBS Group
Zurich,
Switzerland
| – | -$75 | -142 | Closed |
|
12
Morgan Stanley
New York
| – | -$54 | -102 | Closed |
|
|
SS
13
SBI Securities
Tokyo,
Japan
| – | -$26 | -50 | Closed |
|
14
Bank of America
Charlotte,
North Carolina
| – | -$8 | -15 | Closed |
|
15
JP Morgan Chase
New York
| – | -$1 | -1 | Closed |
|
VINC Hedge Fund Activity: Q2 2025 in Review
1 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Vincerx Pharma, Inc. Common Stock (VINC) for Q2 2025, worth a combined $2 — down 100% from $117K a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of VINC and 1 opened new positions — a net loss of 13 holders — while 0 trimmed existing stakes and 0 added.
The largest buyer was Bank & Trust Company, opening a new position worth an estimated $20. The largest seller was Sage Rhino Capital, exiting entirely with an estimated $45.1K sold.
- 1 institutional investor held Vincerx Pharma, Inc. Common Stock (VINC) as of Q2 2025, down from 14 in Q1 2025.
- Funds reported $2 of Vincerx Pharma, Inc. Common Stock stock for Q2 2025, down 100% quarter-over-quarter.
- 1 fund opened new Vincerx Pharma, Inc. Common Stock positions in Q2 2025 and 14 closed out, a net change of -13 holders.
- The largest Vincerx Pharma, Inc. Common Stock buyer in Q2 2025 was Bank & Trust Company, an estimated $20 added.
- The largest Vincerx Pharma, Inc. Common Stock seller in Q2 2025 was Sage Rhino Capital, an estimated $45.1K sold.
Based on aggregated 13F filings for Q2 2025.